Peptide and Anticoagulant Drugs Market

Global Peptide and Anticoagulant Drugs Market Size, Share And Trend Analysis Report By Product (Hormonal, Antibiotic, ACE Inhibitor, Antifungal and Others), By Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology and Others), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025655 | Category : Pharmaceuticals | Delivery Format: /

The global peptide and anticoagulant drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anticoagulants are blood thinners that prevent or reduce coagulation of blood, prolonging the clotting time. These drugs are used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long-chain amino acids. The major factor for the growth of the market include the increasing prevalence of chronic diseases and increasing healthcare expenditure.

According to the Centers for Medicare & Medicaid Services (CMS), in 2020, the US health care spending grew 9.7%, reaching $4.1 trillion and a total of $12,530 per person. Additionally, healthcare spending accounted for 19.7% of the nation's Gross Domestic Product (GDP). Furthermore, according to World Health Organization (WHO), the global healthcare expenditure was 9.8% of the world’s GDP in 2018. Further, according to the National Center for Biotechnology Information (NCBI), approximately one in three of all adults suffer from multiple chronic conditions globally in 2018. Moreover, the rising geriatric population is also driving the growth of the market.

Some major players in the market include Abbott Laboratories, Johnson & Johnson Services, Inc., Bayer AG, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, Nacto Pharma launched a Rivaroxban molecule under the brand name RPIGAT. Rivaroxban is an anticoagulant medication used to prevent blood clots. 

Market Coverage

The market number available for – 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered- 

o By Product

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape-Abbott Laboratories, Johnson & Johnson Services, Inc., Bayer AG, and Pfizer Inc.,among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Peptide and Anticoagulant Drugs Market Report by Segment

By Product

Hormonal

Antibiotic

ACE Inhibitor

Antifungal

Others

By Application

Diabetes

Infectious Diseases

Cancer

Osteoporosis

Cardiology

Gynecology

Others 

Global Peptide and Anticoagulant Drugs Market Report by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa